Lundbeck Q3 2019 Financial Results
Eptinezumab demonstrated rapid onset from Day 1
Key secondary endpoint:
Percentage reduction on Day 1
I
PROMISE-1
PROMISE-2
35%
Eptinezumab 100 mg
60%
PROMISE 1:
-Eptinezumab 300 mg
30%
--Placebo
50%
Eptinezumab 100 mg
Eptinezumab 300 mg
-Placebo
*
Eptinezumab 100mg: 52.3%
25%
*
Eptinezumab 300mg: 54.9%
Placebo: 24.5%
Percent of Patients
40%
Average
20% baseline % of
patients with
migraine on
any given day:
-30%
Average
baseline % of
patients with
30%
migraine on
any given day:
+
15%
10%
PROMISE 2:
10%
5%
*
Eptinezumab 100mg: 50.3%
0%
0%
BL
Day 1
Wk 1
Wk 2
Wk 3
Wk 4
BL
Day 1
Wk 1
Wk 2
Wk 2
Wk 4
-58%
20%
18
Eptinezumab 300mg: 51.6%
*
Placebo: 27.1%
*p=0.0159 vs placebo, unadjusted; +p=0.0312 vs placebo, unadjusted; p<0.0001 vs placebo.
1. Saper J, Wilks K, Chakhava G, et al. Eptinezumab for the Prevention of Episodic Migraine Through 1 Year: Results from the Phase 3
PROMISE-1 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy-1) Trial. Presented at: 2019 American
Academy of Neurology Annual Meeting: Philadelphia, PA; May 4-10, 2019. $38.003 2. Kudrow D, Lipton R, Silberstein S, et al.
Eptinezumab for Prevention of Chronic Migraine: Results of 2 Infusions in the Phase 3 PROMISE-2 (Prevention of Migraine via
Intravenous Eptinezumab Safety and Efficacy-2) Trial. Presented at: 2019 American Academy of Neurology Annual Meeting:
Philadelphia, PA; May 4-10, 2019. P2.10-006
LundbeckView entire presentation